跳转至内容
Merck
CN
  • Down-regulation of CXCL11 inhibits colorectal cancer cell growth and epithelial-mesenchymal transition.

Down-regulation of CXCL11 inhibits colorectal cancer cell growth and epithelial-mesenchymal transition.

OncoTargets and therapy (2018-11-15)
Yu Jie Gao, De Lin Liu, Sheng Li, Gao Feng Yuan, Li Li, Hong Yan Zhu, Guan Yi Cao
摘要

The poor prognosis of colorectal cancer (CRC) largely results from local invasion and tumor metastases. Epithelial-mesenchymal transition (EMT) is a key step in the progression of solid tumors and plays a vital role in tumor metastasis. Recent studies demonstrate that C-X-C motif chemokine 11 (CXCL11) is involved in various cancers' progression. However, its biological activity in CRC needs deeper exploration. The level of CXCL11 in CRC tissues and cell lines was determined using the quantitative real-time PCR (qRT-PCR) assay. The MTT, colony formation, wound healing and Transwell invasion assays were applied to assess the role of CXCL11 in CRC cell growth, migration and invasion, in vitro, respectively. A xenograft model was constructed to analyze the function of CXCL11 in CRC cell growth in vivo. CXCL11 was over-expressed in CRC tissues and cell lines. Repression of CXCL11 significantly inhibited CRC cell migration, invasion and EMT in vitro. In addition, down-regulation of CXCL11 reduced CRC cell growth and metastasis in vivo. Finally, we revealed that repression of CXCL11 inhibited the metastatic ability of CRC cell in a N-cadherin dependent manner. In summary, this study explicates the oncogenic activities of CXCL11 in CRC cell growth and metastasis.

材料
货号
品牌
产品描述

Sigma-Aldrich
MISSION® esiRNA, targeting human CXCL11